Abstract
Single-entity sympathomimetic bronchodilators are often the primary therapeutic modality for asthma in children, especially when avoidance of the systemic adverse effects of the methylxanthines and the corticosteroids is of major concern. Metaproterenol, a recognized beta2 adrenergic agonist resistant to deactivation by catechol-o-methyl-transferase, was the object of two double-blind studies in Denver, among children 6 to 16 years of age, with a confirmed diagnosis of variable obstructive airways disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
